In This Section

Home / Learn / Precision Medicine / Cancer Diagnostics / Measurable Residual Disease Testing

Measurable Residual Disease Testing

As the use of biomarker testing options in the treatment of certain cancers continues to grow, so too do barriers to their use. Underpinning these barriers is a lack of understanding about how biomarker testing works and what impact it can have on selecting the most promising cancer treatment options.  

Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells. MRD speaks to deeper levels of sensitivity to detect disease. 

Monitoring a patient’s MRD at various points throughout active treatment and into remission provides important personalized insights into the effectiveness of a given therapy and may be used to predict which patients are at risk of relapse. Testing for MRD can shape treatment choices and overall patient management to achieve better outcomes. Unfortunately, routine MRD testing is variable, and there are currently no standards for optimal MRD testing. 

On-Demand Webinars

Roadmap Webinar Series

Hear Kelly Terrell share why the MRD webinar series can be so valuable to the care team.

Digital Tools

MRD Testing Implementation Roadmap
Navigate how to lay the groundwork for MRD testing, prepare your care team, implement testing, and evaluate ongoing progress.

MRD Testing Resource Library
Curated materials to help establish and implement MRD testing for your patients with adult B-cell ALL.

Cancer Buzz Podcast

  • [PODCAST] Ep 80: The Promise of MRD Testing in Multiple Myeloma & CLL
    Mar 29, 2022

    While not yet mainstream in the community setting, hear how measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.